Axsome Therapeutics (AXSM) Tops Q1 EPS by $1.03; Offers Operational Guidance

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($0.26), $1.03 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $25.2 million.

Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• AXT appoints Tracy Liu to its board of directors